CTLA4 and melanoma: Several checkpoint inhibitors, e.g., Ipilimumab (a CTLA4-i), Nivolumab and Pembrolizumab (PD-1-i), have been approved to treat melanoma and lung cancer, with demonstrated improved survival [17–23].